Evaluation of Clinical and Ultrasonographic Parameters in Psoriatic Arthritis Patients Treated with Adalimumab: A Retrospective Study

Abstract EN

|Objectives.

The aim of this study was to evaluate clinical and US-PD parameters in PsA during adalimumab treatment.

Methods.

A retrospective study has been conducted in forty patients affected by moderate-to-severe peripheral PsA.

Clinical, laboratory, and US-PD evaluations were performed at baseline, after 4, 12, and 24 weeks of treatment.

They included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), visual analogue scale (VAS), Health Assessment Questionnaire (HAQ) modified for Spondyloarthritis, Psoriasis Area Severity Index (PASI) score, the 28-joint Disease Activity Score (DAS 28), and US-PD assessment.

US-PD findings were scored according to a semiquantitative scale (ranging 0–3) for synovial proliferation (SP), joint effusion (SE), bone erosions (BE), and PD.

Results.

Data obtained for clinical, laboratory findings and US-PD evaluation showed statistical significant improvement in all the measures performed except for BE.

A significant parallel decrease in SE, SP, and PD values were demonstrated.

Conclusion.

This study demonstrated that US-PD is a valid technique in monitoring the response to adalimumab in moderate-to-severe PsA.